HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach to China

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner Andrew von Eschenbach and Deputy Commissioner for International and Special Programs Murray Lumpkin met with China's minister of health and commissioner of China's food and drug agency as the two countries try to finalize a memorandum of agreement on the import safety of food, drugs and medical devices (1"The Tan Sheet" Aug. 20, 2007, p. 14). While withholding details of the MOA, Lumpkin noted that FDA's "preference is obviously not to have to catch problems in the products at our borders ... but prevent them at the source of their manufacturer." Von Eschenbach suggested the MOA will be finalized in early December, in time for HHS Secretary Mike Leavitt's visit to China. The meeting in Shanghai is the latest effort from the Bush administration's Interagency Working Group on Import Safety established in July...

You may also be interested in...



China Commits To Tightening Food Safety Supervision As MOA Talks Begin

A spokesman at the Chinese embassy in Washington says China will intensify its food safety supervision as U.S. and Chinese officials in Beijing begin work on a memorandum of agreement on food and feed safety

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel